Lilly’s Verzenio gets first-line EU approval for HER2- advanced breast cancer

pharmafile | October 3, 2018 | News story | Research and Development, Sales and Marketing Cancer, Eli Lilly, Verzenio, breast cancer, pharma 

The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged.

The therapy has been authorised in the first-line treatment of hormone receptor-positive (HR+), epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, as well as a second-line treatment after earlier endocrine drugs.

The decision was built upon the findings of two trials exploring Verzenio’s efficacy in both first-line and second-line indications.

This latest approval follows authorisation in the US back in February, when it was approved for first-line use. According to Lilly, the drug generated nearly $58 million in sales in the second quarter of this year, up $20 million from the previous quarter.

The manufacturer has also claimed that Verzenio is outperforming Novartis’ Kisqali in terms of new prescriptions, while Lilly also looks to muscle in on the territory occupied by the market leader, Pfizer’s Ibrance.

Matt Fellows

Related Content

national-cancer-institute-kmvohcb-w5g-unsplash_1

AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

FDA announces acceptance and priority review of NDA for LUMISIGHT imagining agent for breast cancer

Lumicell has announced that the US Food and Drug Administration (FDA) has accepted and granted …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

Latest content